Compare FIVE & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVE | GH |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 13.3B |
| IPO Year | 2012 | 2018 |
| Metric | FIVE | GH |
|---|---|---|
| Price | $217.35 | $78.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 19 |
| Target Price | ★ $225.95 | $120.05 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 03-18-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.65 | 6.74 |
| EPS | ★ 6.47 | N/A |
| Revenue | ★ $4,764,147,000.00 | $982,021,000.00 |
| Revenue This Year | $14.40 | $33.30 |
| Revenue Next Year | $9.41 | $28.19 |
| P/E Ratio | $34.78 | ★ N/A |
| Revenue Growth | 22.90 | ★ 32.88 |
| 52 Week Low | $60.81 | $36.36 |
| 52 Week High | $238.40 | $120.74 |
| Indicator | FIVE | GH |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 35.40 |
| Support Level | $208.50 | $54.39 |
| Resistance Level | $233.42 | $114.53 |
| Average True Range (ATR) | 8.87 | 5.45 |
| MACD | -1.40 | 0.07 |
| Stochastic Oscillator | 17.86 | 16.18 |
Five Below Inc is a specialty value retailer offering a broad range of trend-right, high-quality products loved by the kid and the kid in all of customers. The Company's edited assortment of products includes select brands and licensed merchandise. The Company also sells its merchandise on the internet, through the Company's e-commerce website and mobile app, offering home delivery and the option to buy online and pick up in store. Additionally, the Company sells merchandise through on-demand third-party delivery services to enable its customers to shop online and receive convenient delivery. It derives revenue from sales of the Company's merchandise to customers.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.